The content of vascular endothelium growth factor is significantly increased, while the level of matrix metalloproteinase-2 is 2-fold reduced in ovarian cancer tissue compared to benign tumors. A trend to an increase in the levels of matrix metalloproteinases 7 and 9 and reduction of vascular endothelial growth factor type 2 receptors in tumor tissue was also detected. A highly significant negative correlation between the levels of vascular endothelial growth factor and matrix metalloproteinase 2 and positive correlations between vascular endothelial growth factor and matrix metalloproteinase 7, vascular endothelial growth factor and matrix metalloproteinase 9, matrix metalloproteinase 2 and vascular endothelial growth factor type 2 receptors were revealed. In the tumors assayed after preoperative therapy, relative normalization of the studied parameters was observed: the level of vascular endothelial growth factor decreased significantly, while the levels of matrix metalloproteinase 2 and vascular endothelial growth factor type 2 receptors increased. The levels of the markers differed significantly in ovarian tumors of different histological types, and the levels of vascular endothelial growth factor type 2 receptors were higher in patients with stage III compared to stage I and the content of matrix metalloproteinase 7 was higher in stage III compared to stage II cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
E. S. Gershtein, N. V. Levkina, M. A. Digaeva, et al., Byull. Eksp. Biol. Med., 149, No. 5, 562–565 (2010).
P. G. Artini, M. Ruggiero, P. Monteleone, et al., Biomed. Pharmacother., 62, No. 6, 373–377 (2008).
D. Belotti, C. Calcagno, A. Garofalo, et al., Mol. Cancer Res., 6, No. 4, 525–534 (2008).
D. Belotti, P. Paganoni, L. Manenti, et al., Cancer Res., 63, No. 17, 5224–5229 (2003).
K. Q. Cai, W. L. Yang, C. D. Capo-Chichi, et al., Mol. Carcinog., 46, No. 2, 130–143 (2007).
H. Chen, D. Ye, X. Xie, et al., Gynecol. Oncol., 94, No. 3, 630–635 (2004).
F. J. Collinson, G. D. Hall, T. J. Perren, and G. C. Jayson, Expert. Rev. Anticancer Ther., 8, No. 1, 21–32 (2008).
B. Davidson, I. Goldberg, W. H. Gotlieb, et al., Mol. Cell Endocrinol., 187, Nos. 1–2, 39–45 (2002).
E. I. Deryugina and J. P. Quigley, Biochim. Biophys. Acta, 1803, No. 1, 103–120 (2010).
P. Karihtala, J. Mäenpää, T. Turpeenniemi-Hujanen, and U. Puistola, Anticancer Res., 30, No. 3, 1001–1006 (2010).
W. Lu, H. Chen, F. Yel, et al., Eur. J. Gynaecol. Oncol., 27, No. 4, 363–369 (2006).
S. Sillanpaa, M. Anttila, K. Suhonen, et al., Tumour Biol., 28, No. 5, 280–289 (2007).
S. Sillanpaa, M. Anttila, K. Voutilainen, et al., Gynecol. Oncol., 104, No. 2, 296–303 (2007).
F. Q. Wang, J. So, S. Reierstad, and D. A. Fishman, Int. J. Cancer, 118, No. 4, 879–888 (2006).
F. Q. Wang, J. So, S. Reierstad, and D. A. Fishman, Int. J. Cancer, 114, No. 1, 19–31 (2005).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 151, No. 4, pp. 431–435, April, 2011
Rights and permissions
About this article
Cite this article
Gershtein, E.S., Kushlinsky, D.N., Levkina, N.V. et al. Relationship between the Expression of VEGF Signal Components and Matrix Metalloproteinases in Ovarian Tumors. Bull Exp Biol Med 151, 449 (2011). https://doi.org/10.1007/s10517-011-1353-5
Received:
Published:
DOI: https://doi.org/10.1007/s10517-011-1353-5